LENZ Therapeutics (LENZ) Capital Expenditures (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Capital Expenditures of -$1000.0 for Q1 2026, down 100.91% year-over-year from $110000.0 in Q1 2025, and up 99.87% quarter-over-quarter from -$789000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Capital Expenditures (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Capital Expenditures for 7 consecutive years, with -$1000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 100.91% year-over-year to -$1000.0; the TTM figure through Mar 2026 stood at -$111000.0 (down 119.2% YoY), while the FY2024 annual figure was $468000.0, up 4780.0% from the prior year.
- Capital Expenditures rose to -$1000.0 in Q1 2026 per LENZ's latest filing, from -$789000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.3 million in Q1 2022 and bottomed at -$789000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $542384.6 across 5 years, with a median of $149000.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 809.17% — and 2025, when it sank 629.53%.
- LENZ Therapeutics' Capital Expenditures stood at $1.0 million in 2022, then sank by 101.57% to -$16000.0 in 2023, then surged by 1031.25% to $149000.0 in 2024, then tumbled by 629.53% to -$789000.0 in 2025, then jumped by 99.87% to -$1000.0 in 2026.
- Business Quant data shows LENZ's Capital Expenditures at -$1000.0 in Q1 2026, -$789000.0 in Q4 2025, and $585000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 251.02 Mn |
| 10 | LENZ Therapeutics | 147.15 Mn | 147.15 Mn | 5.21 Mn | 16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -789,000.00 |
| Dec 31, 2025 | -789,000.00 |
| Sep 30, 2025 | 585,000.00 |
| Sep 30, 2025 | 585,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |